Antihypertensives and their relation to mortality by SARS-CoV-2 infection
Open Access
- 1 April 2021
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (4), 2467-2475
- https://doi.org/10.1002/jmv.26775
Abstract
The role of antihypertensives, especially Renin-Angiotensin-Aldosterone System inhibitors, is still debatable in COVID-19-related severity and outcome. Therefore, we search for a more global analysis of antihypertensive medication in relation to SAS-CoV-2 severity using prescription data worldwide. The association between the percentage use of different types of antihypertensive medications and mortality rates due to a SARS-CoV-2 infection during the first 3 weeks of the pandemic was analyzed using random effects linear regression models for 30 countries worldwide. Higher percentages of prescribed angiotensin receptor blockers (ARBs) (beta, 95% confidence interval [CI]; -0.02 [-0.04 to -0.0012]; p = .042) and calcium channel blockers (CCBs) (beta, 95% CI; -0.023 [-0.05 to -0.0028]; p = .0304) were associated with a lower first 3-week SARS-CoV-2-related death rate, whereas a higher percentage of prescribed angiotensin-converting enzyme inhibitors (ACEis) (beta, 95% CI; 0.03 [0.0061-0.05]; p = .0103) was associated with a higher first 3-week death rate, even when adjusted for age and metformin use. There was no association between the amount of prescribed beta-blockers (BBs) and diuretics (Diu) and the first 3-week death rate. When analyzing the combination of drugs that is used by at least 50% of antihypertensive users, within the different countries, countries with the lowest first 3-week death rates had at least an angiotensin receptor blocker as one of the most often prescribed antihypertensive medications (ARBs/CCBs: [beta, 95% CI; -0.02 [-0.03 to -0.004]; p = .009], ARBs/BBs: [beta, 95% CI; -0.03 [-0.05 to -0.006]; p = .01]). Finally, countries prescribing high-potency ARBs had lower first 3-week ARBs. In conclusion, ARBs and CCB seem to have a protective effect against death from SARS-CoV-2 infection.This publication has 31 references indexed in Scilit:
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-IndependentHypertension, 2020
- Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart FailurePharmacological Reviews, 2019
- Classic and Nonclassic Renin-Angiotensin Systems in the Critically IllCritical Care Clinics, 2019
- Urine RAS components in mice and people with type 1 diabetes and chronic kidney diseaseAmerican Journal of Physiology-Renal Physiology, 2017
- The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1–7)-Mas axes in pressure overload-induced cardiac remodeling in male miceJournal of Molecular and Cellular Cardiology, 2016
- Replication-dependent downregulation of cellular angiotensin-converting enzyme 2 protein expression by human coronavirus NL63Journal of General Virology, 2012
- Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartanAmerican Journal of Physiology-Renal Physiology, 2009
- A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injuryNature Medicine, 2005
- Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2Circulation, 2005